| Title | Author(s) | Year | View Count |
 | A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B | Lai, CL; Leung, N; Teo, EK; Tong, M; Wong, F; Hann, HW; Han, S; Poynard, T; Myers, M; Chao, G; Lloyd, D; Brown, NA | 2005 | 1,110 |
 | Final Results of a Phase I/II Dose Escalation Trial of Valtorcitabine in Patients with Chronic Hepatitis B | Lim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lloyd, D; Pietropalolo, K; Zhou, XJ; Chao, G; Brown, NA | 2005 | 131 |
| Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: Results of a phase I/II clinical trial. | Lai, CL; Brown, NA; Yuen, RMF; Wai, CT; Lloyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Lim, SG | 2004 | 173 |
| Results of a One-year International Phase IIB Comparative Trial of Telbivudine, Lamivudine, and the Combination, in Patients with Chronic Hepatitis B | Lai, CL; Leung, NWY; Teo, EK; Tong, M; Wong, F; Hann, HW; Han, S; Poynard, T; Myers, M; Chao, G; Lloyd, D; Brown, N | 2003 | 109 |
| Val-LdT: First evidence of efficacy and safety for a new anti-HBV agent | Lim, SG; Lai, CL; Yuen, RMF; Brown, N; Lloyd, D; Myers, M | 2002 | 107 |
| Safety and Antiviral Effects of Val-LdC and LdT in Patients with Chronic Hepatitis B | Lim, SG; Young, DY; Yuen, MF; Myers, M; Lloyd, D; Brown, N; Lai, CL | 2002 | 120 |
|
